Showing 7041-7050 of 8826 results for "".
- Study: Photodynamic Therapy Usage Shifts With Season, Geographyhttps://practicaldermatology.com/news/study-photodynamic-therapy-usage-shifts-with-season-geography/2485308/Seasonal and geographic variation influences the use of photodynamic therapy (PDT) for actinic keratoses (AKs), according to a large cross-sectional study. Reasearchers analyzed over 79 million procedural claims from 2015 to 202
- FDA Approves Once-Daily Oral Semaglutidehttps://practicaldermatology.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- Commentary Flags Risks in Minoxidil Use Among Older Adultshttps://practicaldermatology.com/news/commentary-flags-risks-in-minoxidil-use-among-older-adults/2485231/In a recent commentary published in the Journal of the American Academy of Dermatology, Funda Datli Yakaryilmaz, MD, and Dursun Turkmen, MD, raise concerns about safety monitoring for low-dose oral minoxidil (LDOM) in older
- Systematic Review Suggests Anti-Inflammatory Effects of Astragalus membranaceushttps://practicaldermatology.com/news/systematic-review-shows-anti-inflammatory-effects-of-astragalus-membranaceus/2485129/A new systematic review suggests the traditional botanical Astragalus membranaceus may have clinically relevant anti-aging benefits. "The demand for cosmetic strategies to mitigate [skin ag
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- New Series Spotlights Real Stories of MCC Patientshttps://practicaldermatology.com/news/new-series-spotlights-real-stories-of-mcc-patients/2484808/The Skin Cancer Champions Community announced that it will launch its Living With: Merkel Cell Carcinoma (MCC) web series on Wednesday, January 14, 2026, from 12:00 to 1:00pm EST via Zoom. According to a release from the group, the premiere episode,
- SCRATCH-AD: Rapid-Onset Anti-Itch and Anti-Inflammatory Effects of Ruxolitinib Creamhttps://practicaldermatology.com/news/scratch-ad-rapid-onset-anti-itch-and-anti-inflammatory-effects-of-ruxolitinib-cream/2484591/Results from the SCRATCH-AD study suggested that ruxolitinib cream 1.5% provided itch relief, as well as broader improvements in atopic dermatitis (AD) severity The SCRATCH-AD study evaluated how quickly ruxolitinib 1.5% cream
- Stapokibart Shows Efficacy and Safety in Elderly Patients With ADhttps://practicaldermatology.com/news/stapokibart-shows-efficacy-and-safety-in-elderly-patients-with-ad/2484589/This post hoc analysis evaluated the efficacy and safety of stapokibart, an anti–IL-4Rα monoclonal antibody, in elderly adults with moderate-to-severe atopic dermatitis—a population often characterized by more complex inflammatory signatures and comorbidities. The
- AI Model Accurately Scores Psoriasis Severity from Clinical Imageshttps://practicaldermatology.com/news/ai-model-accurately-scores-psoriasis-severity-from-clinical-images/2484588/A new study demonstrates the potential of artificial intelligence (AI) to improve the consistency and objectivity of psoriasis severity assessments based on 2D clinical images. Researchers for the study used the YOLOv8 deep lear
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin